Standard BioTools Inc. develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines. The Company's segments include Proteomics and Genomics. The Proteomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of genes and their functions. The Company provides insights in health and disease using its mass cytometry and microfluidics technologies, which serve applications in proteomics and genomic. It works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories around the world, focusing on the needs in translational and clinical research, including oncology, immunology, and immunotherapy. The Company also provides differentiated multi-omics tools for research.
企業コードLAB
会社名Standard BioTools Inc
上場日Feb 10, 2011
最高経営責任者「CEO」Dr. Michael Egholm, Ph.D.
従業員数818
証券種類Ordinary Share
決算期末Feb 10
本社所在地2 Tower Place
都市SOUTH SAN FRANCISCO
証券取引所NASDAQ Global Select Consolidated
国United States of America
郵便番号94080
電話番号16502666000
ウェブサイトhttps://www.standardbio.com/
企業コードLAB
上場日Feb 10, 2011
最高経営責任者「CEO」Dr. Michael Egholm, Ph.D.
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし